Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.64 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.60 |
| ▸ | EED | O75530 | 3/20 | 0.52 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.48 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.48 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12180137 | 0.89 | EZH2 (0.65) | EZH2EZH1EEDSUZ12BRD4 | |
| SCHEMBL17584933 | 0.89 | EZH2 (0.53) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL12180391 | 0.88 | EZH2 (0.64) | EZH2EZH1EEDSUZ12BRD4 | |
| SCHEMBL2587499 | 0.88 | EZH2 (0.64) | EZH2EZH1EEDSUZ12BRD4 | |
| SCHEMBL2592559 | 0.88 | EZH2 (0.64) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL30620946 | 0.88 | EZH2 (0.64) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL19620792 | 0.87 | EZH2 (0.63) | EZH2EZH1EEDSUZ12BRD4 | |
| SCHEMBL12180429 | 0.87 | EZH2 (0.62) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL12180107 | 0.87 | EZH2 (0.62) | EZH2EZH1EEDSUZ12BRD4 | |
| SCHEMBL16360922 | 0.87 | EZH2 (0.62) | EZH2EZH1EEDSUZ12BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160074394-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2016-03-17 | — | — | US | disclosed |
| US-20160074394-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074394-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | EZH2 2/4885EZH1 1/4885EED 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.